Publications by authors named "Katie Niland"
Article Synopsis
- Mavorixafor is a new oral drug targeting the CXCR4 receptor, aimed at improving immune cell activity in melanoma patients, tested in a small study alongside the existing treatment pembrolizumab.
- The study found that mavorixafor increased CD8 T-cell presence and other markers of immune activation in tumor samples, suggesting it could enhance immune responses in tumors.
- Safety assessments indicated manageable side effects, supporting the idea that mavorixafor could be a promising option for patients not responding to current treatments.
Article Synopsis
- The CXCR4 receptor helps tumors survive by reducing immune responses against them, and mavorixafor is a drug that inhibits this receptor, potentially boosting the invasion of T-cells that attack cancer.
- In a study involving nine patients with metastatic clear cell renal cell carcinoma who hadn't responded to nivolumab alone, the combination of mavorixafor and nivolumab showed some signs of effectiveness, with one out of five patients with stable disease achieving partial response.
- While some patients experienced serious side effects, the results suggest that targeting CXCR4 with mavorixafor combined with PD-1 inhibition could be a promising strategy for treating these cancers, warranting further research.
Ponatinib is a BCR-ABL tyrosine kinase inhibitor (TKI) approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia in patients resistant or intolerant to prior TKIs. In vitro studies suggested that metabolism of ponatinib is partially mediated by CYP3A4. The effects of CYP3A4 inhibition on the pharmacokinetics of ponatinib and its CYP3A4-mediated metabolite, AP24567, were evaluated in a single-center, randomized, two-period, two-sequence crossover study in healthy volunteers.
View Article and Find Full Text PDF